Insulet Corporation (NASDAQ: PODD) has reported its financial results for the fourth quarter and full year of 2025, showcasing impressive growth and performance. In the fourth quarter of 2025, the company's revenue saw a 31.2% increase to $783.8 million, demonstrating a strong performance that exceeded the high end of the company's guidance range. The total Omnipod revenue also experienced significant growth, rising 33.5% to $781.8 million.
For the full year 2025, Insulet reported a revenue increase of 30.7% to $2.7 billion, surpassing the high end of the company's guidance range. The gross margin for the year improved to 71.6%, up 180 basis points over the prior year, showcasing the company's financial strength.
In terms of operating income, the company reported $146.3 million for the fourth quarter, representing 18.7% of revenue. For the full year, operating income reached $473.8 million, or 17.5% of revenue, up 260 basis points over the prior year.
Adjusted net income for the fourth quarter of 2025 was $109.2 million, or $1.55 per diluted share, reflecting a significant increase of 31.6% and 34.8%, respectively, compared with the prior year. For the full year, adjusted net income rose to $354.4 million, or $4.97 per diluted share, marking a substantial increase of 53.8% and 53.4%, respectively, compared to the prior year.
Insulet's operating cash flow for the year was $569.3 million, compared with $430.2 million in the prior year, demonstrating solid financial performance and cash generation. Furthermore, the company's free cash flow reached $377.7 million, compared with $305.3 million in the prior year, indicating a healthy cash position and financial management.
The company also provided its outlook for 2026, with guidance for both the first quarter and full year. For the first quarter, revenue in constant currency is expected to grow between 25% and 27%, while for the full year, revenue is projected to increase by 20% to 22%. Additionally, adjusted EPS growth for the year is expected to be over 25%, reflecting the company's optimistic outlook for the future.
Insulet's President and CEO, Ashley McEvoy, expressed confidence in the company's ability to grow the global aid market, expand adoption across type 1 and type 2 diabetes, and deliver on strategic and financial commitments. The company's strong performance, innovation, and customer trust position it for long-term success.
Insulet's commitment to delivering long-term value for shareholders is evident in its approval for a $350 million increase in share repurchase authorization. The company expects to fund these repurchases with existing cash, reinforcing its financial strength and disciplined approach to capital deployment.
Insulet's consistent growth, financial performance, and strategic initiatives demonstrate its position as a leader in the medical device industry, with a focus on simplifying life for people with diabetes and other conditions through its innovative products. As a result of these announcements, the company's shares have moved 0.42% on the market, and are now trading at a price of $287.70. Check out the company's full 8-K submission here.
